Oral Semaglutide for Weight Loss: What the Wegovy Pill Means for Singapore

You have been thinking about GLP-1 treatment for a while. You have read the clinical data, seen what it does for hunger and weight, and maybe even spoken to friends who are on it. But there is one thing holding you back: the needle.

You are not alone. For many patients considering oral semaglutide for weight loss, the injection itself is the biggest barrier. Not the cost or the side effects. The needle.

Until recently, the only oral option was Rybelsus, a 14 mg semaglutide tablet approved for type 2 diabetes. It works, but it was never designed as a dedicated weight loss treatment. The dose is lower, and the results reflect that.

That changed on 22 December 2025, when the FDA approved oral Wegovy, a 25 mg semaglutide pill, specifically for weight loss. It is the first and only oral GLP-1 medication with that approval. The clinical trial results show weight loss comparable to the weekly injection.

This article covers what the oral Wegovy approval means, how it compares to Rybelsus and injectable Wegovy, the trial data behind it, and what Singapore patients can expect in the coming years.

What is oral Wegovy and how is it different from Rybelsus?

Both oral Wegovy and Rybelsus contain the same active ingredient: semaglutide. Both come as daily tablets. And both use the same absorption technology, a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which helps the medication survive your stomach acid and reach your bloodstream. Only about 0.8-1% of the oral dose actually gets absorbed, which is why the pill doses are so much higher than the injectable doses.

The difference comes down to dose and indication.

Rybelsus tops out at 14 mg daily. It was developed and approved for type 2 diabetes, with weight loss as a secondary benefit. In the PIONEER trials, patients on Rybelsus 14 mg lost roughly 3-5% of their body weight.

Oral Wegovy goes up to 25 mg daily. It was developed and approved specifically for weight loss. In the OASIS 4 trial, patients on 25 mg lost 13.6% of their body weight over 64 weeks. That is roughly three to four times the weight loss seen with Rybelsus.

The fasting requirement is the same for both: take the pill on an empty stomach with no more than 120 mL of water, then wait at least 30 minutes before eating, drinking, or taking other medications. This is not optional. Food in your stomach significantly reduces absorption.

If you are already taking Rybelsus for weight loss in Singapore, think of oral Wegovy as the next step: same molecule and same format, but at a higher dose with better results.

How much weight loss does the oral semaglutide pill deliver?

Three large clinical trials back higher-dose oral semaglutide. The results are consistent across all three.

OASIS 4 results (the approval trial)

This is the trial the FDA used for the December 2025 approval. Published in the New England Journal of Medicine in September 2025, OASIS 4 enrolled 307 adults with obesity or overweight plus at least one weight-related condition.

After 64 weeks on 25 mg oral semaglutide:

• Patients who stayed on treatment lost an average of 16.6% of their body weight (versus 2.7% on placebo)
• Including dropouts (the ITT analysis), average weight loss was 13.6% versus 2.2%
• 34.4% of adherent patients lost 20% or more of their starting weight
• 71.1% of patients with prediabetes reverted to normal blood sugar levels (versus 33.3% on placebo)

The dropout rate due to side effects was low: 6.9% on the active medication versus 5.9% on placebo.

OASIS 1 results (50 mg dose)

Published in The Lancet in June 2023, OASIS 1 tested a higher 50 mg dose in 667 adults over 68 weeks. The results were even stronger:

• ITT weight loss: 15.1%
• On-treatment weight loss: 17.4%
• 85% of participants lost at least 5% of their body weight
• 69% lost at least 10%
• 54% lost at least 15%

The FDA ultimately approved the 25 mg dose rather than 50 mg, likely balancing efficacy against tolerability.

OASIS 2 results (East Asian population)

This trial matters most for Singapore. OASIS 2 enrolled 201 adults in Japan and South Korea and tested the 50 mg dose over 68 weeks. Weight loss averaged 14.3%.

GLP-1 metabolism can vary across ethnic groups, so seeing strong results in an East Asian population adds confidence that oral semaglutide works well for patients in this region.

Oral Wegovy vs injectable Wegovy: how do they compare?

This is the question most patients ask: do I lose the same amount of weight with a pill as I do with the injection?

Roughly, yes.

The on-treatment numbers slightly favour the pill (16.6% vs 14.9%), while the ITT numbers slightly favour the injection. These trials used different patient populations, so a direct head-to-head comparison has limits. But overall, the two formats deliver comparable weight loss.

The trade-offs come down to convenience and lifestyle fit:

The pill requires daily commitment. You wake up, take it on an empty stomach with a small sip of water, then wait 30 minutes before breakfast. Every single day. If you travel across time zones, if your mornings are chaotic, if you eat breakfast with your children at 6 am, that 30-minute fasting window adds friction.

The injection is once a week. You pick a day, inject with a pre-filled pen (the needle is very small), and you are done for seven days. No daily fasting window. No timing meals around absorption.

For a detailed breakdown of both formats, see our guide to oral vs injectable GLP-1.

Side effects of oral semaglutide for weight loss

The side effect profile of oral semaglutide at the 25 mg weight loss dose is similar to the injectable version, except gastrointestinal side effects are more common with the pill.

From the OASIS 4 data:

• Nausea: 46.6% (versus 18.6% on placebo)
• Vomiting: 30.9% (versus 5.9% on placebo)
• Any gastrointestinal event: 74% (versus 42.2% on placebo)

For comparison, nausea rates with injectable Wegovy in the STEP trials ranged from 30-44% depending on the study. The oral formulation appears to cause somewhat more nausea, possibly because the medication passes directly through the gastrointestinal tract rather than entering through the bloodstream.

Two things worth knowing about these numbers.

The side effects are mostly mild to moderate and temporary. They tend to peak during the dose escalation phase and settle once your body adjusts to the maintenance dose. The gradual step-up schedule (starting at 1.5 mg and reaching 25 mg over about three months) exists specifically to minimise this.

And the discontinuation rate due to side effects was only 6.9%. That means more than 93% of participants tolerated the medication well enough to continue. The side effects were uncomfortable, not unmanageable.

The obvious upside of the pill: no injection site reactions. No redness, bruising, or discomfort at the injection site, because there is no injection site.

Dosing and how to take it

Oral Wegovy follows a gradual dose escalation over roughly three months:

1. Weeks 1-4: 1.5 mg daily
2. Weeks 5-8: 4 mg daily
3. Weeks 9-12: 9 mg daily
4. Week 13 onwards: 25 mg daily (maintenance)

Each step up gives your body time to adjust, which reduces side effects.

The dosing instructions are identical to Rybelsus, and they matter more than most patients realise:

• Take the pill first thing in the morning on a completely empty stomach
• Swallow whole with no more than 120 mL of plain water (about half a glass)
• Do not crush, chew, or split the tablet
• Wait at least 30 minutes before eating, drinking anything else, or taking other medications

These restrictions exist because of how the SNAC absorption enhancer works. It creates a temporary window in your stomach lining that allows semaglutide to pass through. Food, coffee, juice, or even too much water dilutes the SNAC and sharply reduces how much medication your body absorbs.

Common mistakes that reduce absorption:

• Drinking a full glass of water instead of 120 mL
• Taking the pill with coffee or tea
• Eating within the 30-minute window
• Taking other tablets at the same time (they compete for absorption)

If you are already on Rybelsus, you already know this routine. The daily fasting requirement is the same.

What this means for Singapore patients

The practical timeline for Singapore:

Rybelsus (semaglutide 14 mg) has been HSA-approved for type 2 diabetes since June 2021. It is available now and is prescribed off-label for weight loss by clinics across Singapore, including Trimly. At the current dose, it delivers modest weight loss of around 3-5%, which suits some patients but is less than what the higher-dose formulations produce.

Oral Wegovy (semaglutide 25 mg) received FDA approval in December 2025 but is not yet approved by Singapore's Health Sciences Authority (HSA). Based on typical regulatory timelines, HSA approval could come 12-24 months after the FDA, placing it roughly in late 2027 or 2028. Novo Nordisk would also need to ensure adequate supply, given global demand for their semaglutide products.

In the meantime, you have options. Trimly prescribes both oral semaglutide (Rybelsus 14 mg) and injectable Wegovy for weight loss. If you prefer a needle-free approach, Rybelsus gets you started on oral semaglutide today. When oral Wegovy becomes available locally, the transition to the higher dose will be smooth since you will already be familiar with the medication and the dosing routine.

If your priority is maximum weight loss now rather than waiting for the oral option, injectable Wegovy delivers 14.9% weight loss at the current 2.4 mg dose. For more on how the different medications compare, see our medication comparison guide.

Cost is another consideration. Rybelsus currently runs $300-400 per month in Singapore. Pricing for oral Wegovy in Singapore has not been announced. In the United States, the self-pay price ranges from $149-299 per month, though list price is significantly higher. For context on current pricing for all GLP-1 options in Singapore, see our GLP-1 cost guide.

Frequently asked questions about the oral semaglutide weight loss pill

Is oral Wegovy available in Singapore?

Not yet. The FDA approved oral Wegovy in December 2025, but HSA approval has not been granted. Based on typical timelines, it may be available in Singapore by late 2027 or 2028. In the meantime, Rybelsus (oral semaglutide 14 mg) is available and prescribed for weight loss off-label.

Is oral semaglutide as effective as the injection?

At the 25 mg weight loss dose, yes. The OASIS 4 trial showed 16.6% weight loss on treatment, compared to 14.9% for injectable Wegovy in STEP 1. The two formats deliver comparable results at their respective approved doses.

Do I still need to take it on an empty stomach?

Yes. The empty stomach requirement applies to all oral semaglutide formulations, whether Rybelsus or oral Wegovy. You must take it with no more than 120 mL of water and wait 30 minutes before eating.

Can I switch from injectable Wegovy to the pill?

This would need to be discussed with your doctor. The efficacy is comparable, so switching is plausible. The main adjustment would be moving from a weekly routine to a daily one with fasting requirements.

How much will oral Wegovy cost in Singapore?

Unknown at this stage. Rybelsus currently costs $300-400 per month in Singapore. US self-pay pricing for oral Wegovy is $149-299 per month, but Singapore pricing will depend on HSA approval, Novo Nordisk's local pricing strategy, and supply availability.

What about the 50 mg dose tested in OASIS 1?

The OASIS 1 trial tested a 50 mg dose and showed 15.1% ITT weight loss (17.4% on-treatment). The FDA approved the 25 mg dose, which delivered strong results with potentially better tolerability. Whether the 50 mg dose will become available later is unclear.

The bottom line on oral semaglutide for weight loss

• Oral Wegovy (semaglutide 25 mg) received FDA approval on 22 December 2025 as the first oral GLP-1 for weight loss
• Clinical trials show 13.6-16.6% weight loss, comparable to injectable Wegovy
• The OASIS 2 trial confirmed strong results (14.3% weight loss) specifically in East Asian populations
• Side effects are primarily gastrointestinal and tend to settle after the dose escalation phase
• Oral Wegovy is not yet available in Singapore, but Rybelsus (oral semaglutide 14 mg) is available now and prescribed off-label for weight loss
• When oral Wegovy arrives in Singapore, patients already on Rybelsus will have a natural upgrade path

An oral GLP-1 approved specifically for weight loss removes one of the last barriers for patients who want this treatment but cannot get past the idea of weekly injections. The data shows you do not have to compromise on results to avoid a needle.

Oral Wegovy (semaglutide 25 mg for weight loss) is not yet approved by the Health Sciences Authority (HSA) in Singapore and is not available for prescription here. The clinical trial results discussed in this article are from published peer-reviewed studies but may not reflect real-world outcomes. Weight loss results vary depending on individual factors including starting weight, adherence, diet, and exercise. The figures cited come from specific trial populations and dosing regimens. This article is for informational purposes only and does not constitute medical advice. Always consult your doctor before starting, stopping, or changing any medication. Trimly is a MOH-licensed telehealth clinic in Singapore (HCSA License R/25M0505/MDS/001/252).